We are live on !
Find out more
Birchview Capital Portfolio holdings
AUM
$173M
Turnover
41.05%
1-Year Est. Return
89.27%
This Fund
S&P 500
This Quarter Est. Return
+5.97%
1 Year Est. Return
+89.27%
3 Year Est. Return
+315.46%
5 Year Est. Return
+442.13%
10 Year Est. Return
+979.78%
AUM
$194M
AUM Growth
+$4.56M
(+2.4%)
Cap. Flow
+$124K
Cap. Flow % of AUM
Cap. Flow %
0.06%
Top 10 Holdings %
Top 10 Hldgs %
92.1%
Holding
47
New
6
Increased
8
Reduced
4
Closed
7
Avg Time Held
1.6
years
Top 10 Avg Time Held
1.3
years
Top 20 Avg Time Held
1.6
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Neurocrine Biosciences
NBIX
|
+$1.44M |
| 2 |
CFRX
ContraFect
CFRX
|
+$485K |
| 3 |
ICPT
Intercept Pharmaceuticals
ICPT
|
+$463K |
| 4 |
CMTA
Clementia Pharmaceuticals
CMTA
|
+$360K |
| 5 |
XLRN
Acceleron Pharma
XLRN
|
+$347K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene
CELG
|
+$1.91M |
| 2 |
NXTM
NxStage Medical
NXTM
|
+$857K |
| 3 |
PRTK
Paratek Pharmaceuticals
PRTK
|
+$727K |
| 4 |
ADXS
Advaxis Inc
ADXS
|
+$231K |
| 5 |
Opko Health
OPK
|
+$159K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 96.34% |
| 2 | Energy | 2.46% |
| 3 | Industrials | 0.44% |
| 4 | Consumer Staples | 0.37% |
| 5 | Miscellaneous | 0.31% |
Similar funds
AMAL
6SA
Birchview Capital's Q3 2017 Portfolio in Review
As of Q3 2017, Birchview Capital held 47 positions worth $194M, up 2.4% from $189M the previous quarter. Its ten largest holdings account for 92% of the portfolio.
Birchview Capital's Q3 2017 filing shows 6 new, 8 increased, 4 reduced and 7 closed positions. Its largest new stake was Intercept Pharmaceuticals: 4,300 shares worth $250K. The largest sale was Celgene, an estimated $1.91M.
By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 97% a quarter earlier, followed by Energy and Industrials.
- Birchview Capital's largest Q3 2017 buy was Intercept Pharmaceuticals: 4,300 shares worth $250K.
- Birchview Capital added most to Neurocrine Biosciences in Q3 2017, an estimated $1.44M increase.
- Birchview Capital's biggest Q3 2017 reduction was Celgene, cutting an estimated $1.91M.
- Birchview Capital fully exited NxStage Medical in Q3 2017, selling an estimated $857K.
- Birchview Capital's ten largest holdings make up 92% of its $194M portfolio in Q3 2017.
- Birchview Capital opened 6 new positions and closed 7 in Q3 2017.
- Birchview Capital's portfolio value rose 2.4% quarter-over-quarter to $194M.
Based on Birchview Capital's 13F filing for Q3 2017, filed 2 Nov 2017.